Macclesfield, United Kingdom
Nodus Oncology is a biotechnology startup founded in 2022 and headquartered in the United Kingdom. The company's slogan, "Developing next generation DDR targeting therapies," encapsulates its focus on developing first and best-in-class molecules inhibiting novel targets within the DNA damage response and replication stress response. Leveraging the most recent scientific advances, Nodus Oncology is at the forefront of developing the next wave of cancer therapeutics in the DNA damage response (DDR) area.
Backed by Cumulus Oncology and in partnership with the Lead Discovery Center, Nodus Oncology is strategically positioned to make significant strides in the biotechnology industry. The company's innovative portfolio is centered on synthetic lethality and collateral vulnerabilities in molecularly defined cancer patient populations. In February 2023, Nodus Oncology secured a significant £2.40M Seed Round investment from KHAN Technology Transfer Fund and Cumulus Oncology, signaling confidence in the company's potential and direction.
With its cutting-edge approach and strong financial support, Nodus Oncology is well-positioned to create a meaningful impact in the biotechnology landscape and potentially revolutionize cancer therapeutics through its pioneering DDR targeting therapies.
